Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19669193rdf:typepubmed:Citationlld:pubmed
pubmed-article:19669193lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19669193lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:19669193lifeskim:mentionsumls-concept:C0024314lld:lifeskim
pubmed-article:19669193lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:19669193lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:19669193lifeskim:mentionsumls-concept:C0011929lld:lifeskim
pubmed-article:19669193lifeskim:mentionsumls-concept:C0017516lld:lifeskim
pubmed-article:19669193pubmed:issue3lld:pubmed
pubmed-article:19669193pubmed:dateCreated2010-3-23lld:pubmed
pubmed-article:19669193pubmed:abstractTextThe objective of the study was to evaluate the feasibility of a UK-based real-time service to improve the diagnosis and management of lymphoproliferative disorders (LPDs) in Ghana. Adult patients reporting to hospital with a suspected LPD, during a 1 year period, were prospectively enrolled. Bone marrow and/or lymph node biopsies were posted to the Haematology Malignancy Diagnostic Service (HMDS), Leeds, UK and underwent morphological analysis and immunophenotyping. Results were returned by e-mail. The initial diagnoses made in Ghana were compared with the final HMDS diagnoses to assess the contribution of the HMDS diagnosis to management decisions. The study was conducted at the two teaching hospitals in Ghana-Komfo Anokye, Kumasi and Korle Bu, Accra. Participants comprised 150 adult patients (>/=12 years old), 79 women, median age 46 years. Bone marrow and lymph node biopsy samples from all adults presenting with features suggestive of a LPD, at the two teaching hospitals in Ghana, over 1 year were posted to a UK LPD diagnostic centre, where immunophenotyping was performed by immunohistochemistry. Molecular analysis was performed where indicated. Diagnostic classifications were made according to international criteria. Final diagnosis was compared to the initial Ghanaian diagnosis to evaluate discrepancies; implications for alterations in treatment decisions were evaluated. Median time between taking samples and receiving e-mail results in Ghana was 15 days. Concordance between initial and final diagnoses was 32% (48 of 150). The HMDS diagnosis would have changed management in 31% (46 of 150) of patients. It is feasible to provide a UK-based service for LPD diagnosis in Africa using postal services and e-mail. This study confirmed findings from wealthy countries that a specialised haematopathology service can improve LPD diagnosis. This model of Ghana-UK collaboration provides a platform on which to build local capacity to operate an international quality diagnostic service for LPDs.lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:languageenglld:pubmed
pubmed-article:19669193pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19669193pubmed:statusPubMed-not-MEDLINElld:pubmed
pubmed-article:19669193pubmed:issn1865-5785lld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:Bedu-AddoGeor...lld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:OwenRoger GRGlld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:BatesImeldaIlld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:ParkinsElizab...lld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:SemOhene...lld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:EkemIvyIlld:pubmed
pubmed-article:19669193pubmed:authorpubmed-author:AdomakohYvonn...lld:pubmed
pubmed-article:19669193pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19669193pubmed:volume2lld:pubmed
pubmed-article:19669193pubmed:ownerNLMlld:pubmed
pubmed-article:19669193pubmed:authorsCompleteYlld:pubmed
pubmed-article:19669193pubmed:pagination143-9lld:pubmed
pubmed-article:19669193pubmed:year2009lld:pubmed
pubmed-article:19669193pubmed:articleTitleUK-based real-time lymphoproliferative disorder diagnostic service to improve the management of patients in Ghana.lld:pubmed
pubmed-article:19669193pubmed:publicationTypeJournal Articlelld:pubmed